Role of cytochrome P450 3A4 in human metabolism of MK-639, a potent human immunodeficiency virus protease inhibitor.

MK-639 (L-735,524) is a potent human immunodeficiency virus protease inhibitor under investigation in the treatment of acquired immunodeficiency syndrome. Five in vitro approaches have been used to identify the cytochrome P450 isoform(s) responsible for the human microsomal oxidative metabolism of MK-639. These approaches are: 1) chemical inhibition; 2) immunochemical inhibition; 3) metabolism by cDNA-expressed human cytochrome P450 enzymes; 4) a correlation analysis; and 5) competitive inhibition of marker activities. Ketoconazole and troleandomycin, both selective inhibitors for cytochrome P450 3A4 (CYP3A4), markedly inhibited the formation of all oxidative metabolites of MK-639; whereas other inhibitors (furafylline, sulfaphenazole, quinidine, S-mephenytoin, and diethyldithiocarbamate) had little effect on MK-639 metabolism. This suggested the involvement of CYP3A4 in MK-639 metabolism. Consistent with this, an anti-rat CYP3A1 rabbit polyclonal antibody, which shows a cross-reactive inhibition of CYP3A4-dependent testosterone 6beta-hydroxylation in human liver microsomes, completely inhibited MK-639 metabolism. Human recombinant CYP3A4 showed a high metabolic activity to form all MK-639 metabolites found in native human liver microsomes. In addition, the formation of individual MK-639 metabolites correlated well with each other and with testosterone 6beta-hydroxylation in 12 different human liver microsomes, whereas no correlation was observed between MK-639 metabolite formation and bufuralol 1'-hydroxylation (or tolbutamide methyl hydroxylation). Furthermore, MK-639 strongly inhibited testosterone 6beta-hydroxylation in a concentration-dependent manner. Kinetic analysis showed that MK-639 is a very potent competitive inhibitor for testosterone 6beta-hydroxylation, with a Ki value of approximately 0.5 mu M. Collectively, these results consistently indicate that CYP3A4 is the isoform responsible for the oxidative metabolism of MK-639 in human liver microsomes.

• Publication year

  1996

• Venue

  Drug Metabolism And Disposition

• Publication date

  1996-03-01

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1016/s0090-9556(25)07348-9PMID 8820421
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Cytochrome P450 inhibitors. Evaluation of specificities in the in vitrometabolism of therapeutic agents by human liver microsomes.

  1995cited by this paper
• L-735,524: an orally bioavailable human immunodeficiency virus type 1 protease inhibitor.

  1994cited by this paper
• Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians.

  1994cited by this paper
• Isoform-selective mechanism-based inhibition of human cytochrome P450 1A2 by furafylline.

  1993cited by this paper
• Stereo- and regioselective N- and S-oxidation of tertiary amines and sulfides in the presence of adult human liver microsomes.

  1993cited by this paper
• Metabolism of gestodene in human liver cytosol and microsomes in vitro.

  1993cited by this paper
• The human hepatic cytochromes P450 involved in drug metabolism.

  1992cited by this paper
• Effects of imidazole derivatives on cytochromes P450 from human hepatocytes in primary culture

  1992cited by this paper
• Oxidation of toxic and carcinogenic chemicals by human cytochrome P-450 enzymes.

  1991cited by this paper
• Role of human cytochrome P-450 IIE1 in the oxidation of many low molecular weight cancer suspects.

  1991cited by this paper
• Measurement of enzyme activities of cytochrome P-450 isoenzymes by high-performance liquid chromatographic analysis of products.

  1991cited by this paper
• Separation of human liver microsomal tolbutamide hydroxylase and (S)-mephenytoin 4'-hydroxylase cytochrome P-450 enzymes.

  1991cited by this paper
• Furafylline is a potent and selective inhibitor of cytochrome P450IA2 in man.

  1990cited by this paper
• Tolbutamide and mephenytoin hydroxylation by human cytochrome P450s in the CYP2C subfamily.

  1990cited by this paper
• Comparison of levels of several human microsomal cytochrome P-450 enzymes and epoxide hydrolase in normal and disease states using immunochemical analysis of surgical liver samples.

  1990cited by this paper
• Cytochrome P-450 hPCN3, a novel cytochrome P-450 IIIA gene product that is differentially expressed in adult human liver. cDNA and deduced amino acid sequence and distinct specificities of cDNA-expressed hPCN1 and hPCN3 for the metabolism of steroid hormones and cyclosporine.

  1989cited by this paper
• Expression of a human liver cytochrome P-450 protein with tolbutamide hydroxylase activity in Saccharomyces cerevisiae.

  1989cited by this paper
• Tolbutamide hydroxylation by human liver microsomes. Kinetic characterisation and relationship to other cytochrome P-450 dependent xenobiotic oxidations.

  1988cited by this paper
• In vitro inhibition studies of tolbutamide hydroxylase activity of human liver microsomes by azoles, sulphonamides and quinolines.

  1988cited by this paper
• Oxidation of quinidine by human liver cytochrome P-450.

  1986cited by this paper
• Identification of an inducible form of cytochrome P-450 in human liver.

  1985cited by this paper
• Competitive inhibition of sparteine oxidation in human liver by beta-adrenoceptor antagonists and other cardiovascular drugs.

  1984cited by this paper
• THE CARBON MONOXIDE-BINDING PIGMENT OF LIVER MICROSOMES. I. EVIDENCE FOR ITS HEMOPROTEIN NATURE.

  1964cited by this paper
• Protein measurement with the Folin phenol reagent.

  1951cited by this paper

• Therapeutically targeting the consequences of HIV-1-associated gastrointestinal dysbiosis: Implications for neurocognitive and affective alterations.

  2023cites this paper
• Involvement of CYP3A4 and MDR1 in altered metabolism and transport of indinavir in 1,25(OH)2D3-treated Caco-2 cells.

  2023cites this paper
• Identification of potential antivirals against SARS-CoV-2 using virtual screening method

  2021cites this paper
• St. John’s Wort: A Therapeutic Herb to Be Cautioned for Its Potential Neurotoxic Effects and Major Drug Interactions

  2021cites this paper
• Kinetics of cytochrome P450 3A4 inhibition by heterocyclic drugs defines a general sequential multistep binding process

  2020cites this paper
• Substrates of Human CYP2D6

  2018cites this paper
• GIT Anatomy and Physiology and Drug Oral Bioavailability: Impact of Species Differences

  2017cites this paper
• Differences in the Prediction of Area Under the Curve for a Protease Inhibitor Using Trough Versus Peak Concentration: Assessment Using Published Pharmacokinetic Data for Indinavir

  2017cites this paper
• Tin Selenide Quantum Dots Electrochemical Biotransducer for the Determination of Indinavir - A Protease Inhibitor Anti-Retroviral Drug

  2016cites this paper
• Clinical Drug-Drug Interaction Data: Effects of Antiretroviral Agents on Co-administered Drugs

  2016cites this paper
• In Vitro Reaction Phenotyping and Drug Interaction Data

  2016cites this paper
• The Role of Metabolizing Enzymes and Transporters in Antiretroviral Therapy.

  2016cites this paper
• Tin Selenide Quantum Dots Electrochemical Biotransducer for the Determination of Indinavir - A Protease Inhibitor Anti-Retroviral Drug

  2016cites this paper
• Pharmacokinetic and Pharmacodynamic Drug Interactions Associated with Antiretroviral Drugs

  2016cites this paper
• Development of an enantioselective assay for simultaneous separation of venlafaxine and O-desmethylvenlafaxine by micellar electrokinetic chromatography-tandem mass spectrometry: Application to the analysis of drug-drug interaction.

  2015cites this paper
• Indinavir

  2012cites this paper
• Lack of Indinavir Effects on Methadone Disposition Despite Inhibition of Hepatic and Intestinal Cytochrome P4503A (CYP3A)

  2012cites this paper
• Impact of the Herbal Medicine Sophora flavescens on the Oral Pharmacokinetics of Indinavir in Rats: The Involvement of CYP3A and P-Glycoprotein

  2012cites this paper
• The cellular pharmacokinetics of HIV protease inhibitors: current knowledge and future perspectives.

  2012cites this paper
• Herb-Drug Interactions

  2012cites this paper
• In vitro-to-in vivo predictions of drug–drug interactions involving multiple reversible inhibitors

  2012cites this paper
• Combination therapy of Western drugs and herbal medicines: recent advances in understanding interactions involving metabolism and efflux

  2012cites this paper
• Drug-Food Interactions

  2011cites this paper
• Effect of protease inhibitors (indinavir and ritonavir) on the pharmacokinetics of gliclazide in rabbits

  2011cites this paper
• Anatomical and Physiological Factors Affecting Oral Drug Bioavailability in Rats, Dogs, and Humans

  2011cites this paper
• Twenty-six years of HIV science: an overview of anti-HIV drugs metabolism

  2011influential citation
• Pre-Clinical and Clinical Pharmacology of 17alpha-Hydroxyprogesterone caproate (17-OHPC): An Agent for the Prevention of Preterm Birth.

  2010cites this paper
• Pharmacokinetic Interaction between Indinavir and Darunavir with Low-Dose Ritonavir in Healthy Volunteers

  2010cites this paper
• Structure and mechanism of the complex between cytochrome P4503A4 and ritonavir

  2010cites this paper
• Drug–Herb Interactions in Patients with HIV/AIDS

  2010cites this paper
• Pharmacogenomics of CYP3A: considerations for HIV treatment.

  2009cites this paper
• HIV Therapeutics: Antiretroviral Drugs and Immune-Based Therapies

  2009cites this paper
• Consequences of Vitamin D and Xenobiotic Metabolism by Cytochrome P450 in HIV infection.

  2009cites this paper
• Substrate specificity, inhibitors and regulation of human cytochrome P450 2D6 and implications in drug development.

  2009cites this paper
• Interplay of transporters and enzymes in drug and metabolite processing.

  2009cites this paper
• Novel therapeutic biosensor for indinavir-a protease inhibitor antiretroviral drug.

  2009cites this paper
• Inhibition and induction of human cytochrome P450 enzymes: current status

  2008cites this paper
• Effects of Pregnancy on CYP3A and P‐glycoprotein Activities as Measured by Disposition of Midazolam and Digoxin: A University of Washington Specialized Center of Research Study

  2008cites this paper
• Clinical drugs that interact with St. John's wort and implication in drug development.

  2008cites this paper
• Identification of Enzymes Involved in the Metabolism of 17α-Hydroxyprogesterone Caproate: An Effective Agent for Prevention of Preterm Birth

  2008cites this paper
• The challenges of dealing with promiscuous drug-metabolizing enzymes, receptors and transporters.

  2008cites this paper
• An update on clinical drug interactions with the herbal antidepressant St. John's wort.

  2008cites this paper
• A novel approach to the prediction of drug-drug interactions in humans based on the serum incubation method.

  2008cites this paper
• Impact of physiological, physicochemical and biopharmaceutical factors in absorption and metabolism mechanisms on the drug oral bioavailability of rats and humans

  2007cites this paper
• Pharmacokinetic interaction between rifampicin and ritonavir‐boosted atazanavir in HIV‐infected patients *

  2007cites this paper
• INTO THE CONTROL OF SMALL ARTERY FUNCTION IN HUMAN PREGNANCY AND ESTROGEN RECEPTOR ETA KNOCKOUT MICE

  2007cites this paper
• Indinavir/ritonavir remains an important component of HAART for the treatment of HIV/AIDS, particularly in resource-limited settings

  2007cites this paper
• Impact of physiological, physicochemical and biopharmaceutical factors in absorption and metabolism mechanisms on the drug oral bioavailability of rats and humans.

  2007cites this paper
• New insights into the control of small artery function in human pregnancy and estrogen receptor beta knockout mice

  2007cites this paper
• Differential inhibition of cytochrome P450 3A4, 3A5 and 3A7 by five human immunodeficiency virus (HIV) protease inhibitors in vitro.

  2006cites this paper
• Toxicokinetics: Fundamentals and Applications in Drug Development and Safety Assessment

  2006cites this paper
• Drug Interactions with St. John's Wort and Echinacea

  2006cites this paper
• Possible Drug–Metabolism Interactions of Medicinal Herbs with Antiretroviral Agents

  2006cites this paper
• MDR- and CYP3A4-mediated drug-herbal interactions.

  2006cites this paper
• Drug Bioactivation Covalent Binding to Target Proteins and Toxicity Relevance

  2005cites this paper
• Bridging cheminformatic metabolite prediction and tandem mass spectrometry.

  2005cites this paper
• Drug Metabolism and Transport

  2005cites this paper
• Pharmacokinetic Interactions of Drugs with St John’s Wort

  2004cites this paper
• Indinavir and Rifabutin Drug Interactions in Healthy Volunteers

  2004influential citation
• Integration of knowledge-based metabolic predictions with liquid chromatography data-dependent tandem mass spectrometry for drug metabolism studies: application to studies on the biotransformation of indinavir.

  2004cites this paper
• Therapeutic drugs that behave as mechanism-based inhibitors of cytochrome P450 3A4.

  2004cites this paper
• Pharmacokinetic interaction between rifampin and the combination of indinavir and low-dose ritonavir in HIV-infected patients.

  2004cites this paper
• Influence of Goldenseal Root on the Pharmacokinetics of Indinavir

  2003cites this paper
• Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir.

  2003cites this paper
• The design, synthesis and evaluation of novel HIV-1 protease inhibitors with high potency against PI-resistant viral strains.

  2003cites this paper
• HIV protease inhibitors with picomolar potency against PI-Resistant HIV-1 by extension of the P3 substituent.

  2003cites this paper
• Computation of Log BB Values for Compounds Transported Through Carrier-Mediated Mechanisms Using in Vitro Permeability Data from Brain Microvessel Endothelial Cell (BMEC) Monolayers

  2003cites this paper
• A randomized trial of 2 different 4-drug antiretroviral regimens versus a 3-drug regimen, in advanced human immunodeficiency virus disease.

  2003cites this paper
• Novel HIV-1 protease inhibitors active against multiple PI-resistant viral strains: coadministration with indinavir.

  2003cites this paper
• HIV-1 protease inhibitors with picomolar potency against PI-resistant HIV-1 by modification of the P1' substituent.

  2003cites this paper
• Population Pharmacokinetics and Pharmacodynamics of Efavirenz, Nelfinavir, and Indinavir: Adult AIDS Clinical Trial Group Study 398

  2003cites this paper
• Drug–phytochemical interactions

  2003cites this paper
• Steady‐state pharmacokinetic interaction of modified‐dose indinavir and rifabutin

  2003cites this paper
• Summary of information on human CYP enzymes: human P450 metabolism data

  2002cites this paper
• Intestinal metabolism promotes regional differences in apical uptake of indinavir: coupled effect of P-glycoprotein and cytochrome P450 3A on indinavir membrane permeability in rat.

  2002cites this paper
• De novo design and discovery of cyclic HIV protease inhibitors capable of displacing the active-site structural water molecule.

  2002cites this paper
• Pharmacokinetic interactions between herbal remedies and medicinal drugs

  2002cites this paper
• Structural elucidation of metabolites of ritonavir and indinavir by liquid chromatography-mass spectrometry.

  2002cites this paper
• Indinavir Pharmacokinetics during Different Phases of the Menstrual Cycle in HIV-Infected Women

  2002cites this paper
• Synthesis and activity of novel HIV protease inhibitors with improved potency against multiple PI-resistant viral strains.

  2002cites this paper
• Psychosocial and Public Health Impacts of New HIV Therapies

  2002cites this paper
• Pharmacokinetics of Protease Inhibitors and Drug Interactions with Psychoactive Drugs

  2002cites this paper
• Preparation of the HIV-infected traveler to the tropics

  2001cites this paper
• P450 interaction with farnesyl-protein transferase inhibitors metabolic stability, inhibitory potency, and P450 binding spectra in human liver microsomes.

  2001cites this paper
• Saquinavir Soft Gelatin Capsule

  2001cites this paper
• P450 interaction with HIV protease inhibitors: relationship between metabolic stability, inhibitory potency, and P450 binding spectra.

  2001cites this paper
• P-glycoprotein-mediated efflux of indinavir metabolites in Caco-2 cells expressing cytochrome P450 3A4.

  2001cites this paper
• Pharmacokinetic Profile and Tolerability of Indinavir-Ritonavir Combinations in Healthy Volunteers

  2001cites this paper
• Prediction of Metabolic Drug Interactions: Quantitative or Qualitative?

  2001cites this paper
• Combination Therapy with Indinavir, Ritonavir, and Delavirdine and Nucleoside Reverse Transcriptase Inhibitors in Patients with HIV/AIDS Who Have Failed Multiple Antiretroviral Combinations

  2001cites this paper
• Interactions of HIV protease inhibitors with a human organic cation transporter in a mammalian expression system.

  2000cites this paper
• Comparative in vitro metabolism of indinavir in primates - a unique stereoselective hydroxylation in monkey

  2000cites this paper
• Oral delivery of HIV-protease inhibitors.

  2000cites this paper
• Plasma population pharmacokinetics and penetration into cerebrospinal fluid of indinavir in combination with zidovudine and lamivudine in HIV-1-infected patients

  2000cites this paper
• Increased Incidence of Indinavir Nephrolithiasis in Patients with Hepatitis B or C Virus Infection

  2000cites this paper
• Dual protease inhibitor therapy in the management of the HIV-1

  2000cites this paper
• Protease inhibitor-induced carbamazepine toxicity.

  2000cites this paper
• Protease Inhibitor-Induced Carbamazepine Toxicity

  2000influential citation
• Fixed drug eruptions to human immunodeficiency virus-1 protease inhibitor.

  2000cites this paper
• Atherosclerosis in AIDS: potential pathogenetic roles of antiretroviral therapy and HIV.

  2000cites this paper